Frontlight ResearchEarly access
SuspendedNo phase
Evolution of the Therapeutic Care in Ovarian Cancer From 2011
Key facts
- Who runs it
- UNICANCER
- Where
- France20 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- People taking part
- 13,331 people enrolled
- Started
- 1 Apr 2017
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Record updated
- 27 May 2026
- Why it stopped
- enrolment temporariliy stopped for budget considerations
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- 18 years old female
- Female who received surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, diagnostic procedure, other specific therapeutic procedure) for ovarian cancer in a French Comprehensive Cancer Center
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The ESME Ovarian Cancer database is a multi-center real life database using a retrospective data collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites). This database compiles data from existing data available from patient's electronic medical records (EMR).
The group in the trial
- Ovarian cancer cohort
Any female treated for ovarian cancer in a French comprehensive cancer centers
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database : Evolution of the Therapeutic Care in Ovarian Cancer Across the French Comprehensive Cancer Centers From 2011
- Publications
- Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2026
- PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.The oncologist, 2025
- Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2025
- Record updated
- 27 May 2026